These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 36280289)

  • 1. Association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case-control study.
    Collie S; Saggers RT; Bandini R; Steenkamp L; Champion J; Gray G; Bekker LG; Goga A; Garrett N; Patricios J
    Br J Sports Med; 2023 Feb; 57(4):205-211. PubMed ID: 36280289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Bekker LG; Garrett N; Goga A; Fairall L; Reddy T; Yende-Zuma N; Kassanjee R; Collie S; Sanne I; Boulle A; Seocharan I; Engelbrecht I; Davies MA; Champion J; Chen T; Bennett S; Mametja S; Semenya M; Moultrie H; de Oliveira T; Lessells RJ; Cohen C; Jassat W; Groome M; Von Gottberg A; Le Roux E; Khuto K; Barouch D; Mahomed H; Wolmarans M; Rousseau P; Bradshaw D; Mulder M; Opie J; Louw V; Jacobson B; Rowji P; Peter JG; Takalani A; Odhiambo J; Mayat F; Takuva S; Corey L; Gray GE; ;
    Lancet; 2022 Mar; 399(10330):1141-1153. PubMed ID: 35305740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
    Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
    JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.
    Corchado-Garcia J; Zemmour D; Hughes T; Bandi H; Cristea-Platon T; Lenehan P; Pawlowski C; Bade S; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Wagner T; Soundararajan V
    JAMA Netw Open; 2021 Nov; 4(11):e2132540. PubMed ID: 34726743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of national Covid-19 vaccination Campaign, South Korea.
    Yi S; Choe YJ; Lim DS; Lee HR; Kim J; Kim YY; Kim RK; Jang EJ; Lee S; Park E; Kim SJ; Park YJ
    Vaccine; 2022 Jun; 40(26):3670-3675. PubMed ID: 35570077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
    Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
    Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study.
    Homan T; Mazzilli S; Chieti A; Musa A; Roth A; Fortunato F; Bisceglia L; Prato R; Lopalco PL; Martinelli D
    Sci Rep; 2022 Nov; 12(1):18597. PubMed ID: 36329239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study.
    Wright BJ; Tideman S; Diaz GA; French T; Parsons GT; Robicsek A
    Lancet Respir Med; 2022 Jun; 10(6):557-565. PubMed ID: 35227415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of COVID-19 vaccines in patients taking immunosuppressants.
    Shen C; Risk M; Schiopu E; Hayek SS; Xie T; Holevinski L; Akin C; Freed G; Zhao L
    Ann Rheum Dis; 2022 Jun; 81(6):875-880. PubMed ID: 35197265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System.
    Semenzato L; Botton J; Baricault B; Deloumeaux J; Joachim C; Sylvestre E; Dray-Spira R; Weill A; Zureik M
    PLoS One; 2022; 17(9):e0274309. PubMed ID: 36084113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
    Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study.
    Piernas C; Patone M; Astbury NM; Gao M; Sheikh A; Khunti K; Shankar-Hari M; Dixon S; Coupland C; Aveyard P; Hippisley-Cox J; Jebb SA
    Lancet Diabetes Endocrinol; 2022 Aug; 10(8):571-580. PubMed ID: 35780805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.
    Anderegg N; Althaus CL; Colin S; Hauser A; Laube A; Mäusezahl M; Wagner M; Zaffora B; Riou J
    Swiss Med Wkly; 2022 Apr; 152():w30163. PubMed ID: 35752951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis.
    Ssentongo P; Ssentongo AE; Voleti N; Groff D; Sun A; Ba DM; Nunez J; Parent LJ; Chinchilli VM; Paules CI
    BMC Infect Dis; 2022 May; 22(1):439. PubMed ID: 35525973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.